Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Building a Follow-On Business: $3 Billion Reasons to Love Biosimilars

This article was originally published in RPM Report

Executive Summary

One Wall Street analyst thinks biosimilars could represent a $3 billion dollar business line for Amgen in less than a decade. Is that attractive enough to pursue a follow-on strategy for innovator companies? The answer is an unqualified yes.

You may also be interested in...

Biosimilars Naming Conventions On FTC Agenda – In More Ways Than One

An planned Federal Trade Commission hearing on biosimilar competition will include discussion of the debate over the right approach to non-proprietary names. But FTC may be reopening another naming debate by referring to the hearing topic as “follow-on biologics.”

Words Of Wisdom For Biosimilar Developers

FDA has learned a lot from its biosimilar meetings and sponsor discussions so far – including the areas sponsors struggle with and how others might improve their understanding going forward.

BIO Responds On Naming

The Biotechnology Industry Organization submitted the following letter in response to this article, after it was published on-line in July.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts